ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Jan 19, 2023 10:35 JST
Source:
Eisai
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
TOKYO, Jan 19, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Israel Ltd., a pharmaceutical sales subsidiary recently established in Tel Aviv in the State of Israel (Israel). Eisai Israel is a wholly-owned subsidiary of Eisai's European regional headquarters, Eisai Europe Ltd.
Israel's pharmaceutical market reached 5.3 billion USD in 2021.1 The compound annual growth rate of the Israel pharmaceutical market from 2018 to 2021 was +8.56%1 and the market is expected to continue to grow steadily, with a high penetration rate of innovative medicines.
In 2011, Eisai Europe started business in Israel marketing and selling Eisai products through local distribution partners, and mainly marketed Lenvima, Halaven, Fycompa and Inovelon. Eisai Israel was established in August 2021, and in January 2023, became the marketing authorization holder of the Eisai products in Israel. Eisai Israel will now perform sales and marketing activities for these products. The company plans to launch its other global brands in the future.
With the commencement of operations at Eisai Israel, Eisai aims to utilize its own drug sales system in Israel, deliver innovative new drugs to more patients in Israel as quickly as possible, and contribute to improving the benefits of patients and their families.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer
May 29, 2023 15:00 JST
Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer
May 29, 2023 15:00 JST
Toyota: Development and Verification of Stationary Storage Battery System Using Electric Vehicle Storage Batteries
May 29, 2023 13:31 JST
Mitsubishi Electric and Mitsubishi Heavy Industries Definitively Agree to Integrate Their Power-generator Systems Businesses
May 29, 2023 11:24 JST
Liquid Hydrogen-Powered Corolla to Participate in the Super Taikyu Fuji 24 Hours Race
May 29, 2023 09:08 JST
Imposing island challenge awaits TOYOTA GAZOO Racing
May 26, 2023 17:35 JST
Results of a Collision Test Conducted on the Driver's Side of a Toyota RAIZE
May 26, 2023 15:07 JST
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 26, 2023 14:15 JST
'Fujitsu Technology and Service Vision 2023': sustainability and business converge to solve society's challenges
May 26, 2023 10:12 JST
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
May 25, 2023 21:02 JST
TOYOTA GAZOO Racing Opens Le Mans 24 Hours Special Website
May 25, 2023 18:28 JST
Hitachi Enhances Diversity, Equity and Inclusion by Supporting LGBTQIA+ Community
May 25, 2023 18:22 JST
Hitachi: Commencement of Joint Studies on Business Initiatives Towards the Development of Sustainable Finance
May 25, 2023 16:10 JST
MHI Thermal Systems to Release Fully Revamped 3HP Model in "HyperInverter" Series of Packaged Air-Conditioners for Domestic Market
May 25, 2023 12:02 JST
SumUp partners with JCB to boost card acceptance for European merchants within its 4-million-strong global network
May 25, 2023 12:00 JST
Mazda 787B to Demonstrate at 24 Hours of Le Mans Centenary Anniversary
May 25, 2023 10:43 JST
Honda to Participate in FIA Formula One World Championship from 2026 Season as Power Unit Supplier for Aston Martin Aramco Cognizant Formula One Team
May 24, 2023 19:01 JST
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
May 24, 2023 18:03 JST
Mitsubishi Power to Develop Hydrogen-Ready Power Plant for Sembcorp Industries
May 24, 2023 16:06 JST
Mitsubishi Shipbuilding Completes Delivery of Ammonia Fuel Supply System for Large, Low-Speed Two Stroke Marine Engines
May 24, 2023 09:41 JST
More Latest Release >>
Related Release
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
5/26/2023 2:15:00 PM JST
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
5/25/2023 9:02:00 PM JST
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
5/24/2023 6:03:00 PM JST
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
5/20/2023 10:20:00 AM JST
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
5/16/2023 9:27:00 AM JST
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
5/8/2023 11:15:00 AM JST
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
4/6/2023 6:32:00 PM JST
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal
4/4/2023 1:23:00 PM JST
Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System
4/3/2023 1:06:00 PM JST
Eisai Presented New Analyses of Aria and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting
3/31/2023 4:51:00 PM JST
More Press release >>